Scisparc issued u.s. patent for its core technology that treats central nervous systems disorders

Tel aviv, israel, jan. 4, 2022 /prnewswire/ -- scisparc ltd. (nasdaq: sprc), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "company" or "scisparc"), marks today one of the company's most important milestones to date - the u.s. patent and trademark office has granted it a new patent - u.s. patent no.
SPRC Ratings Summary
SPRC Quant Ranking